A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

NCT ID: NCT05202262

Last Updated: 2026-01-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 645 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-12
• Study Completion Date: 2025-02-26

Brief Summary

This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.

Detailed Description

This is a Phase III randomized, double-blind, active comparison, parallel group, multicenter study comparing BFF MDI 320/9.6 μg to BD MDI 320 µg and open-label Symbicort TBH 320/9 μg in adult and adolescent participants who have asthma which remains inadequately controlled (ACQ-7 total score ≥ 1.5) despite treatment with medium dose ICS or ICS/LABA. Budesonide and Formoterol Fumarate MDI 160/9.6 μg is included in this study to evaluate dose response by comparing to BFF MDI 320/9.6 μg. All doses represent the sum of 2 actuations. All study interventions will be administered BID for 24 weeks.

This study will be conducted at approximately 125 sites worldwide and will randomize approximately 630 adult and adolescent participants.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

BFF MDI 320/9.6 μg

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg

Group Type: EXPERIMENTAL

BFF MDI 320/9.6 μg

Intervention Type: DRUG

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg

BFF MDI 160/9.6 μg

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg

Group Type: EXPERIMENTAL

BFF MDI 160/9.6 μg

Intervention Type: DRUG

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg

BD MDI 320 μg

Budesonide MDI (BD MDI), 320 μg

Group Type: EXPERIMENTAL

BD MDI 320 μg

Intervention Type: DRUG

Budesonide MDI (BD MDI), 320 μg

Open-label Symbicort TBH 320/9 μg

Open-Label Comparator Symbicort Turbuhaler 320/9 μg

Group Type: ACTIVE_COMPARATOR

Open-label Symbicort TBH 320/9 μg

Intervention Type: DRUG

Open-label Symbicort Turbuhaler 320/9 μg

Interventions

BFF MDI 320/9.6 μg

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg

Intervention Type: DRUG

BFF MDI 160/9.6 μg

Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg

Intervention Type: DRUG

BD MDI 320 μg

Budesonide MDI (BD MDI), 320 μg

Intervention Type: DRUG

Open-label Symbicort TBH 320/9 μg

Open-label Symbicort Turbuhaler 320/9 μg

Intervention Type: DRUG

Other Intervention Names

BFF; BFF; BD; Symbicort TBH

Eligibility Criteria

Inclusion Criteria

1. 12 to 80 years of age, male and female, BMI <40 kg/m2; females must be not of childbearing potential or using a form of highly effective birth control.

2. Participants who have a documented history of physician-diagnosed asthma ≥ 6 months prior to Visit 1, according to GINA guidelines [GINA 2020]. Healthcare records for one year prior to Visit 1 must be provided for adolescent participants (12 to < 18 years of age) to ensure consistent evaluation and follow-up of treatment in those participants.

3. Participants who have been regularly using a stable daily ICS or an ICS/LABA regimen (including a stable ICS dose), with the ICS doses, for at least 8 weeks prior to Visit 1.

4. ACQ-7 total score ≥ 1.5 at Visits 1 and 4.

5. Pre-bronchodilator/pre-dose FEV1 <90% predicted normal value at Visits 1, 2 and 3, and a pre-dose FEV1 of 50% to 90% at Visit 4 (pre-randomization).

6. Reversibility to albuterol, defined as a post-albuterol increase in FEV1 of ≥ 12% and ≥ 200 mL for participants ≥ 18 years of age OR a post-albuterol increase in FEV1 of ≥ 12% for participants 12 to < 18 years of age, either in the 12 months prior to Visit 1 or at Visit 2 or Visit 3.

7. A pre-bronchodilator/pre-dose FEV1 at Visits 2, 3, and 4 that have not changed 20% or more (increase or decrease) from the pre-bronchodilator/pre-dose FEV1 recorded at the previous visit.

8. Asthma stability during run-in based on Investigator discretion using the symptom worsening assessment.

9. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol.

10. Demonstrate acceptable MDI administration technique.

11. eDiary compliance ≥ 70% during screening, defined as completing the daily eDiary and answering "Yes" to taking 2 puffs of run-in BD MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization.

Exclusion Criteria

1. Life-threatening asthma as defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s).

2. Any respiratory infection or asthma exacerbation treated with systemic corticosteroids and/or additional ICS treatment in the 8 weeks prior to Visit 1 and throughout the Screening Period.

3. Hospitalization for asthma within 8 weeks of Visit 1.

4. Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neurological, endocrine, gastrointestinal, or pulmonary (eg, active tuberculosis, bronchiectasis, pulmonary eosinophilic syndromes, and COPD). Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or that could affect the efficacy or safety analysis.

5. Known history of drug or alcohol abuse within 12 months of Visit 1.

6. Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1.

7. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer. Any other study intervention that is not identified in this protocol is prohibited for use during study duration.

8. Previous or current randomization into studies within the AEROSPHERE program including KALOS, LOGOS, VATHOS, LITHOS, or any glycopyrronium studies (PT001).

9. Use of a nebulizer or a home nebulizer for receiving asthma medications.

10. Do not meet the stable dosing period prior to Visit 1 or unable to abstain from protocol-defined prohibited medications during Screening and Treatment Periods.

11. Receipt of COVID-19 vaccine (regardless of vaccine delivery platform, eg, vector, lipid nanoparticle) < 7 days prior to Visit 1 (from last vaccination or booster dose).

12. Participants with known hypersensitivity to beta2-agonists, corticosteroids, or any component of the MDI.

13. Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, vital signs, or ECG, which in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study.

14. Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months prior to Visit 1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana).

15. Planned hospitalization during the study.

16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.

18. Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.

19. For women only - currently pregnant (confirmed with positive highly sensitive urine pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable contraception measures, as judged by the Investigator.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Chandler, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Bakersfield, California, United States

Research Site

Fresno, California, United States

Research Site

Huntington Beach, California, United States

Research Site

La Palma, California, United States

Research Site

Lincoln, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Newport Beach, California, United States

Research Site

Northridge, California, United States

Research Site

Sacramento, California, United States

Research Site

San Diego, California, United States

Research Site

San Diego, California, United States

Research Site

San Jose, California, United States

Research Site

Denver, Colorado, United States

Research Site

Wheat Ridge, Colorado, United States

Research Site

Cutler Bay, Florida, United States

Research Site

DeLand, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Peoria, Illinois, United States

Research Site

Lexington, Kentucky, United States

Research Site

White Marsh, Maryland, United States

Research Site

North Dartmouth, Massachusetts, United States

Research Site

Farmington Hills, Michigan, United States

Research Site

Columbia, Missouri, United States

Research Site

Saint Charles, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Kalispell, Montana, United States

Research Site

Missoula, Montana, United States

Research Site

Bellevue, Nebraska, United States

Research Site

Omaha, Nebraska, United States

Research Site

Henderson, Nevada, United States

Research Site

North Las Vegas, Nevada, United States

Research Site

Portsmouth, New Hampshire, United States

Research Site

Skillman, New Jersey, United States

Research Site

Gastonia, North Carolina, United States

Research Site

Monroe, North Carolina, United States

Research Site

Raleigh, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Edmond, Oklahoma, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Portland, Oregon, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Knoxville, Tennessee, United States

Research Site

Austin, Texas, United States

Research Site

Beaumont, Texas, United States

Research Site

Boerne, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

El Paso, Texas, United States

Research Site

Forney, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Red Oak, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Victoria, Texas, United States

Research Site

Waco, Texas, United States

Research Site

Williamsburg, Virginia, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Calgary, Alberta, Canada

Research Site

Calgary, Alberta, Canada

Research Site

Edmonton, Alberta, Canada

Research Site

Kamloops, British Columbia, Canada

Research Site

Winnipeg, Manitoba, Canada

Research Site

Moncton, New Brunswick, Canada

Research Site

Ajax, Ontario, Canada

Research Site

Burlington, Ontario, Canada

Research Site

Stouffville, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Windsor, Ontario, Canada

Research Site

Windsor, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Frankfurt am Main, , Germany

Research Site

Landsberg, , Germany

Research Site

Leipzig, , Germany

Research Site

Leipzig, , Germany

Research Site

Leipzig, , Germany

Research Site

Magdeburg, , Germany

Research Site

München-Pasing, , Germany

Research Site

Schleswig, , Germany

Research Site

Wiesbaden, , Germany

Research Site

Witten, , Germany

Research Site

Brescia, , Italy

Research Site

Mantova, , Italy

Research Site

Napoli, , Italy

Research Site

Roma, , Italy

Research Site

Roma, , Italy

Research Site

Rome, , Italy

Research Site

Tradate, , Italy

Research Site

Chūōku, , Japan

Research Site

Chūōku, , Japan

Research Site

Chūōku, , Japan

Research Site

Chūōku, , Japan

Research Site

Fukui-shi, , Japan

Research Site

Fukuoka, , Japan

Research Site

Himeji-shi, , Japan

Research Site

Kagoshima, , Japan

Research Site

Kishiwada-shi, , Japan

Research Site

Kodaira-shi, , Japan

Research Site

Kokubunji-shi, , Japan

Research Site

Kusatsu-shi, , Japan

Research Site

Kyoto, , Japan

Research Site

Kyoto, , Japan

Research Site

Mizunami-shi, , Japan

Research Site

Obihiro-shi, , Japan

Research Site

Osaka, , Japan

Research Site

Sapporo, , Japan

Research Site

Setagaya-ku, , Japan

Research Site

Shibuya-ku, , Japan

Research Site

Toon-shi, , Japan

Research Site

Toshima-ku, , Japan

Research Site

Toshima-ku, , Japan

Research Site

Toshima-ku, , Japan

Research Site

Utsunomiya, , Japan

Research Site

Yokohama, , Japan

Research Site

Yokohama, , Japan

Research Site

Yokohama, , Japan

Research Site

Badalona, , Spain

Research Site

Barcelona, , Spain

Research Site

Bilbao, , Spain

Research Site

Granada, , Spain

Research Site

Granada, , Spain

Research Site

Madrid, , Spain

Research Site

Santiago de Compostela, , Spain

Research Site

Vigo, , Spain

Research Site

Hanoi, , Vietnam

Research Site

Ho Chi Minh City, , Vietnam

Countries

United States; Canada; Germany; Italy; Japan; Spain; Vietnam

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5982C00006&amp;attachmentIdentifier=cea6c9d8-e6e7-4bb9-b601-c8925bd2cf01&amp;fileName=D5982C00006_VATHOS_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier=

CSR Synopsis

Other Identifiers

2024-513568-24-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

2021-002026-24

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D5982C00006

Identifier Type: -

Identifier Source: org_study_id